A compact CRISPR-Cas9 activator was engineered and validated for efficacy of transcriptional activation using AAV delivery in several cell lines.
The development of a compact CRISPR-Cas9 activator enables AAV-mediated delivery for in vivo transcriptional modulation, overcoming previous packaging capacity limitations.
Abstract Akin to Zinc Finger and Transcription Activator Like Effector based transcriptional modulators, nuclease-null CRISPR-Cas9 provides a groundbreaking programmable DNA binding platform, begetting an arsenal of targetable regulators for transcriptional and epigenetic perturbation, by either directly tethering, or recruiting, transcription enhancing effectors to either component of the Cas9/guide RNA complex. Application of these programmable regulators is now gaining traction for the modulation of disease-causing genes or activation of therapeutic genes, in vivo . Adeno-Associated Virus (AAV) is an optimal delivery vehicle for in vivo delivery of such regulators to adult somatic tissue, due to the efficacy of viral delivery with minimal concerns about immunogenicity or integration. However, present Cas9 activator systems are notably beyond the packaging capacity of a single AAV delivery vector capsid. Here, we engineer a compact CRISPR-Cas9 activator for convenient AAV-mediated delivery. We validate efficacy of the CRISPR-Cas9 transcriptional activation using AAV delivery in several cell lines.
Vora et al. (Sun,) reported a other. Compact CRISPR-Cas9 activator was evaluated on Efficacy of CRISPR-Cas9 transcriptional activation. A compact CRISPR-Cas9 activator was engineered and validated for efficacy of transcriptional activation using AAV delivery in several cell lines.